How GlaxoSmithKline Is Partnering To Develop And Distribute COVID-19 Vaccines

As part of its response to COVID 19, GlaxoSmithKline (GSK) is collaborating with several partners in accelerating the development of promising vaccines, by providing access to its patented adjuvant technology. An adjuvant is a substance which, when added to some vaccines, enhances the immune response, promoting stronger and longer lasting immunity against infection.

GlaxoSmithKline has teamed up with Sanofi to produce an adjuvant enhanced vaccine candidate that’s undergoing a Phase 2b clinical trial in February 2021. Canadian biopharmaceutical company Medicago is also collaborating with GSK to combine adjuvant technology with a plant-derived vaccine candidate that may become available in the first half of 2021.

Building on their existing relationship, GSK and CureVac are jointly developing next generation mRNA vaccines for COVID-19 in February 2021, which have the potential to address multiple emerging variants.

Elsewhere, GSK Consumer Healthcare is giving supply chain priority to actions that deliver more products which are in high demand, due to COVID-19. These efforts include increasing production for pain relief brands, multi-vitamins, and dietary supplements.

Reference: “Our response to COVID-19,” GlaxoSmithKline